



February 04, 2026

Ref: - GHL/2025-26/EXCH/98

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub:** Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('*Listing Regulations*')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('**GHL/Company**') at its meeting held today i.e. Wednesday, February 04, 2026, has *inter alia*, approved followings:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine-months ended December 31, 2025 ('**Results**');

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Annexure A** pursuant to Regulation 33 of the Listing Regulations.


2. Appointment of Mr. Malik Mohd. Ashhab as one of the 'Senior Management Personnel' of the Company, designated as 'Head-Diagnostic Services'. Necessary disclosure in this regard as mandated under the Listing Regulations is attached herewith as **Annexure B**.

Further, the Board recommended followings to the Shareholders for their consideration and approval:

- a) Re-appointment of Dr. Ravi Gupta (DIN:00023487) as an Independent Director of the Company for second term of 5 (five) consecutive years w.e.f. July 08, 2026;
- b) Re-appointment of Mr. Rajan Bharti Mittal (DIN:00028016) as an Independent Director of the Company for second term of 5 (five) consecutive years w.e.f. July 08, 2026; and
- c) Appointment of Ms. Shonan Purie Trehan (DIN:07078955) as a Non-Executive Non-Independent Director of the Company, liable to retire by rotation, w.e.f. March 13, 2026.

Necessary disclosures under the Listing Regulations in respect of aforesaid proposals are annexed herewith as **Annexure C, D and E** respectively.

The Company shall seek the approval of Members for aforesaid re-appointment/appointment, through Postal Ballot and the Notice of Postal Ballot, will be sent to all the Members of the Company whose names appear on the Register of Members/List of Beneficial Owners as received from Depositories, as on **Friday, February 6, 2026 ('Cut-off date')**.






The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

The meeting of the Board of Directors commenced at 2.00 P.M. and concluded at 03:15 P.M.

Thanking You,

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**  
**Encl: a/a**



# Walker Chandiok & Co LLP

Walker Chandiok & Co LLP  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram - 122 002  
India

T +91 124 462 8099  
F +91 124 462 8001

## Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') for the quarter ended 31 December 2025 and the year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

# Walker Chandiok & Co LLP

## Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

5. We draw attention to note 4 to the accompanying Statement which describes that a Scheme of Arrangement (the 'Scheme') entered into between the Company and Medanta Holdings Private Limited, an erstwhile wholly-owned subsidiary of the Company, has been approved by the National Company Law Tribunal, New Delhi, vide order dated 20 February 2025. As per such Scheme, the subsidiary has been amalgamated with the Company with effect from the appointed date of the Scheme, being 01 April 2024. The aforesaid Scheme has been given accounting effect in the accompanying Statement in accordance with Appendix C to Ind AS 103, Business Combination of Entities Under Common Control, as prescribed in the Scheme, and consequently, comparative financial information of the prior period presented in the Statement have has been restated, the impact of which is further detailed in the said note.

Our conclusion is not modified in respect of this matter.

**For Walker Chandiok & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No. 507892



UDIN: 26507892NMGTVL8122

**Place:** Gurugram  
**Date:** 04 February 2026

**Chartered Accountants**

**Global Health Limited**  
**Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India**  
**Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India**  
**CIN:L85110DL2004PLC128319**  
**Tel: +91 124 483 4060; E-mail: [compliance@medanta.org](mailto:compliance@medanta.org); Website: <https://www.medanta.org>**  
**Statement of standalone unaudited financial results for the quarter and nine months ended 31 December 2025**

S No.	Particulars	(₹ in millions, unless otherwise stated)					
		Quarter ended			Nine months ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited (Restated) (Refer note 4)	Unaudited	Unaudited (Restated) (Refer note 4)	Audited
<b>I</b>	<b>Income</b>						
I	Revenue from operations	9,401.65	9,264.28	8,123.67	27,487.49	24,012.78	32,041.46
II	Other income	246.64	228.00	194.69	706.03	652.63	909.29
	<b>Total income</b>	<b>9,648.29</b>	<b>9,492.28</b>	<b>8,318.36</b>	<b>28,193.52</b>	<b>24,665.41</b>	<b>32,950.75</b>
<b>III</b>	<b>Expenses</b>						
I	Cost of materials consumed	2,018.33	2,032.16	1,871.73	5,972.12	5,434.37	7,158.13
II	Purchases of stock-in-trade	(5.67)	(0.44)	110.93	19.48	345.67	403.90
	Changes in inventories of stock-in-trade	5.98	0.52	(2.73)	46.11	(5.83)	26.24
	Employee benefits expense	2,523.00	2,483.33	1,849.98	7,335.78	5,608.75	7,462.91
	Finance costs	130.80	88.83	84.62	276.21	262.92	333.91
	Depreciation and amortisation expense	478.63	374.28	373.54	1,186.99	1,116.31	1,496.11
	Retainers and consultants fee	1,510.78	1,282.33	1,013.53	3,885.92	2,974.08	4,038.72
	Other expenses	1,605.58	1,540.65	1,264.01	4,612.89	3,957.52	5,301.40
	<b>Total expenses</b>	<b>8,267.43</b>	<b>7,801.66</b>	<b>6,565.61</b>	<b>23,335.50</b>	<b>19,693.79</b>	<b>26,221.32</b>
<b>IV</b>	<b>Profit before exceptional items and tax</b>	<b>1,380.86</b>	<b>1,690.62</b>	<b>1,752.75</b>	<b>4,858.02</b>	<b>4,971.62</b>	<b>6,729.43</b>
V	Exceptional items (refer note 5)	352.00	(159.85)	-	(3.77)	-	498.96
	<b>Profit before tax</b>	<b>1,028.86</b>	<b>1,850.47</b>	<b>1,752.75</b>	<b>4,861.79</b>	<b>4,971.62</b>	<b>6,230.47</b>
<b>VI</b>	<b>Tax expenses</b>						
I	Current tax	247.52	358.62	396.60	1,019.41	1,246.88	1,608.65
II	Tax pertaining to earlier years	(25.45)	-	-	(25.45)	-	6.88
	Deferred tax charge/(credit)	7.72	89.86	42.29	147.13	43.56	(0.34)
	<b>Profit after tax</b>	<b>799.07</b>	<b>1,401.99</b>	<b>1,313.86</b>	<b>3,720.70</b>	<b>3,681.18</b>	<b>4,615.28</b>
<b>VIII</b>	<b>Other comprehensive income</b>						
I	(i) Items that will not be reclassified to statement of profit or loss	6.36	(10.67)	34.14	(1.30)	17.26	(12.94)
II	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(1.60)	2.69	(8.59)	0.33	(4.34)	3.26
	<b>Total other comprehensive income</b>	<b>4.76</b>	<b>(7.98)</b>	<b>25.55</b>	<b>(0.97)</b>	<b>12.92</b>	<b>(9.68)</b>
<b>IX</b>	<b>Total comprehensive income</b>	<b>803.83</b>	<b>1,394.01</b>	<b>1,339.41</b>	<b>3,719.73</b>	<b>3,694.10</b>	<b>4,605.60</b>
X	Paid-up equity share capital (face value of ₹ 2 each)	537.58	537.58	537.17	537.58	537.17	537.17
XI	Reserves (other equity)						34,438.91
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and nine months)	2.97	5.22	4.89	13.84	13.75	17.18
	Basic (₹ per share)	2.97	5.22	4.89	13.82	13.75	17.18
	Diluted (₹ per share)	2.97	5.22	4.89			

*See accompanying notes to the standalone unaudited financial results*



**Global Health Limited**

**Notes to the standalone unaudited financial results :**

- 1 The above standalone financial results of Global Health Limited ('the Company') for the quarter and nine months ended on 31 December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 February 2026 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment.
- 4 The Board of Directors of the Company ("Board") at its meeting held on 21 March 2024, had approved the Scheme of amalgamation ("the Scheme") of Medanta Holdings Private Limited (wholly-owned subsidiary) with the Company, subject to all the necessary statutory / regulatory approvals.

The Scheme had been approved by the Hon'ble National Company Law Tribunal ('NCLT') vide Order dated 20 February 2025 with appointed date being 01 April 2024. The Scheme became effective on 01 March 2025 upon filing of the certified true copy of the Order with the Registrar of Companies, NCLT of Delhi & Haryana with effect from appointed date.

Accordingly, the Company had accounted for the business combination transaction in accordance the accounting treatment prescribed by the Scheme which is consistent with the principles of Appendix C of Ind AS 103 'Business Combinations under Common Control. Pursuant to above, the comparative financial information of the Company in respect of the prior period has been restated as if the aforesaid business combination had occurred from the beginning of the preceding period, irrespective of the actual date of the combination. The impact of the amalgamation on the previous period is as under:

Particulars	(₹ in millions, unless otherwise stated)		
	As per published financial results for the quarter ended 31 December 2024	Adjustments on account of amalgamation	Post amalgamation for the quarter ended 31 December 2024 (Restated)
Revenue from operations	6,244.04	1,879.63	8,123.67
Profit before tax	1,323.10	429.65	1,752.75
Profit after tax	993.05	320.81	1,313.86
Earnings per share (₹ per share)	3.70	1.19	4.89

Particulars	(₹ in millions, unless otherwise stated)		
	As per published financial results for the nine months ended 31 December 2024	Adjustments on account of amalgamation	Post amalgamation for the nine months ended 31 December 2024 (Restated)
Revenue from operations	19,004.59	5,008.19	24,012.78
Profit before tax	4,056.62	915.00	4,971.62
Profit after tax	3,000.55	680.63	3,681.18
Earnings per share (₹ per share)	11.17	2.58	13.75

**5 Exceptional items include:**

Particulars	Quarter ended					Nine months ended	Year ended
	31 December 2025		30 September 2025		31 December 2024		
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited		
Export Promotion Capital Goods (EPCG) Obligation (Refer point a below)	-	-	-	-	(195.92)	-	-
Stamp duty on merger (Refer point b below)	-	(159.85)	-	-	(159.85)	-	498.96
Impact of new Labour Codes (Refer point c below)	352.00	-	-	-	352.00	-	-
<b>Total</b>	<b>352.00</b>	<b>(159.85)</b>	<b>-</b>	<b>-</b>	<b>(3.77)</b>	<b>-</b>	<b>498.96</b>

a During the quarter ended 30 June 2025, the Company reversed interest liability on EPCG amounting to ₹ 195.92 millions, pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. The Company has achieved the required export obligation within the prescribed timeline.

b During the quarter ended 30 September 2025, the Company reversed stamp duty payable to Government of National Capital Territory of Delhi on account of the merger of Medanta Holding Private Limited and the Company, amounting to ₹ 159.85 millions, pursuant to adjudication of its stamp duty application.



**Global Health Limited****Notes to the standalone unaudited financial results (cont'd) :**

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued draft Central Rules and related FAQs.

The Company has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Company has presented the incremental charge relating to gratuity and compensated absences, aggregating to ₹352.00 millions under 'Exceptional items' in its standalone unaudited financial results for the quarter and nine months ended 31 December 2025.

The Company continues to monitor the finalisation of the Central and State Rules and any further government clarifications on other aspects of the Labour Codes, and will record the accounting treatment as required based on future developments.

- 6 The Company received in-principle approval for the allotment of 3.5 acres of land from Assam Industrial Development Corporation Limited (a Government of Assam undertaking) during the quarter ended 30 September 2025. Further, during the quarter ended 31 December 2025, the Company obtained physical possession of the land.
- 7 During the period ended 31 December 2025, the Board of Directors of the Company has approved the grant of 605,500 Options to certain eligible employees and allotted 183,000 shares to GHL Employees Welfare Trust under Part –A and Part- B respectively of Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024.

**Employee benefits expense includes:**

Particulars	Quarter ended				Nine months ended		(₹ in millions)
	31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Employee share based payment expense	100.15	95.72	-	271.59	-	-	

8 The unaudited standalone financial results also include the financial information of GHL Employees Welfare Trust.

9 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited



Dr. Naresh Trehan  
Chairman and Managing Director

Place : Gurugram  
Date : 04 February 2026

*a*

# Walker Chandiok & Co LLP

Walker Chandiok & Co LLP  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram - 122 002  
India

T +91 124 462 8099  
F +91 124 462 8001

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2025 and the consolidated year to date results for the period 1 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

# Walker Chandiok & Co LLP

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP  
Chartered Accountants  
Firm Registration No: 001076N/N500013



**Tarun Gupta**  
Partner  
Membership No. 507892

UDIN: 26507892ZPAQJD4653



Place: Gurugram  
Date: 04 February 2026

# Walker Chandiok & Co LLP

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)**

## Annexure 1

### List of entities included in the Statement

S. No.	Name	Relationship with Holding Company
1	Global Health Patliputra Private Limited	Wholly owned subsidiary
2	GHL Pharma & Diagnostic Private Limited	Wholly owned subsidiary
3	GHL Hospital Limited	Subsidiary
4	Global Health Institute of Medical Sciences Foundation	Wholly owned subsidiary



**Global Health Limited**  
 Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India  
 Corporate Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana - 122001, India  
 CIN:L85110DL2004PLC128319  
 Tel: +91 124 483 4060; E-mail: [compliance@medanta.org](mailto:compliance@medanta.org); Website: <https://www.medanta.org>  
 Statement of consolidated unaudited financial results for the quarter and nine months ended 31 December 2025

S. No.	Particulars	Quarter ended			Nine months ended		(₹ in millions, unless otherwise stated)
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	<b>Income</b>						
I	Revenue from operations	11,210.47	10,992.22	9,434.36	32,511.06	27,610.68	36,923.15
II	Other income	217.82	197.26	160.24	619.65	561.67	790.97
	<b>Total income</b>	<b>11,428.29</b>	<b>11,189.48</b>	<b>9,594.60</b>	<b>33,130.71</b>	<b>28,172.35</b>	<b>37,714.12</b>
III	<b>Expenses</b>						
	Cost of materials consumed	2,267.15	2,266.92	2,066.01	6,664.84	5,984.81	7,899.60
	Purchases of stock-in-trade	289.28	287.84	206.99	895.02	719.50	924.61
	Changes in inventories of stock-in-trade	0.16	0.80	19.04	(57.14)	(43.81)	(27.52)
	Employee benefits expense	2,806.73	2,743.34	2,050.17	8,114.11	6,204.88	8,245.42
	Finance costs	215.09	171.12	162.75	524.06	502.29	652.59
	Depreciation and amortisation expense	611.88	497.26	484.46	1,560.22	1,444.94	1,937.48
	Retainers and consultants fee	1,793.95	1,549.45	1,249.43	4,710.40	3,657.51	4,973.43
	Other expenses	1,880.24	1,834.46	1,465.07	5,431.61	4,564.04	6,136.98
	<b>Total expenses</b>	<b>9,864.48</b>	<b>9,351.19</b>	<b>7,703.92</b>	<b>27,843.12</b>	<b>23,034.16</b>	<b>30,742.59</b>
IV	<b>Profit before exceptional items and tax</b>	<b>1,563.81</b>	<b>1,838.29</b>	<b>1,890.68</b>	<b>5,287.59</b>	<b>5,138.19</b>	<b>6,971.53</b>
	Exceptional items (refer note 4)	365.98	(159.85)	-	10.21	-	498.96
V	<b>Profit before tax</b>	<b>1,197.83</b>	<b>1,998.14</b>	<b>1,890.68</b>	<b>5,277.38</b>	<b>5,138.19</b>	<b>6,472.57</b>
VI	<b>Tax expenses</b>						
	Current tax	247.52	358.62	396.59	1,019.41	1,246.88	1,608.65
	Tax pertaining to earlier years	(25.45)	-	-	(25.45)	-	6.88
	Deferred tax charge	25.43	55.52	65.51	159.27	91.91	43.86
VII	<b>Profit after tax</b>	<b>950.33</b>	<b>1,584.00</b>	<b>1,428.58</b>	<b>4,124.15</b>	<b>3,799.40</b>	<b>4,813.18</b>
VIII	<b>Other comprehensive income</b>						
	(i) Items that will not be reclassified to statement of profit or loss	8.28	(12.34)	38.36	(0.95)	21.33	(9.13)
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(2.08)	3.11	(9.53)	0.25	(5.29)	2.43
	<b>Total other comprehensive income</b>	<b>6.20</b>	<b>(9.23)</b>	<b>28.83</b>	<b>(0.70)</b>	<b>16.04</b>	<b>(6.70)</b>
IX	<b>Total comprehensive income</b>	<b>956.53</b>	<b>1,574.77</b>	<b>1,457.41</b>	<b>4,123.45</b>	<b>3,815.44</b>	<b>4,806.48</b>
	<b>Profit after tax attributable to:</b>						
	(i) Owners of the Holding Company	950.22	1,584.41	1,429.07	4,124.72	3,800.37	4,814.37
	(ii) Non-controlling interests	0.11	(0.41)	(0.49)	(0.57)	(0.97)	(1.19)
	<b>Other comprehensive income attributable to:</b>						
	(i) Owners of the Holding Company	6.20	(9.23)	28.83	(0.70)	16.04	(6.70)
	(ii) Non-controlling interests	-	-	-	-	-	-
	<b>Total comprehensive income attributable to:</b>						
	(i) Owners of the Holding Company	956.42	1,575.18	1,457.90	4,124.02	3,816.41	4,807.67
	(ii) Non-controlling interests	0.11	(0.41)	(0.49)	(0.57)	(0.97)	(1.19)
X	Paid-up equity share capital (face value of ₹ 2 each)	537.58	537.58	537.17	537.58	537.17	537.17
XI	Reserves (other equity)						33,326.93
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters and nine months)						
	Basic (₹ per share)	3.54	5.89	5.32	15.35	14.14	17.92
	Diluted (₹ per share)	3.54	5.89	5.32	15.32	14.14	17.92

See accompanying notes to the consolidated unaudited financial results



**Global Health Limited**

**Notes to the consolidated unaudited financial results:**

- 1 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter and nine months ended 31 December 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 February 2026 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the healthcare services as single business segment.

**4 Exceptional items include:**

Particulars	Quarter ended			Nine months ended		(₹ in millions)
	31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
Export Promotion Capital Goods (EPCG) Obligation (Refer point a below)	-	-	-	(195.92)	-	-
Stamp duty on merger (Refer point b below)	-	(159.85)	-	(159.85)	-	498.96
Impact of new Labour Codes (Refer point c below)	365.98	-	-	365.98	-	-
<b>Total</b>	<b>365.98</b>	<b>(159.85)</b>	<b>-</b>	<b>10.21</b>	<b>-</b>	<b>498.96</b>

a During the quarter ended 30 June 2025, the Holding Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions, pursuant to the filing of merger order with Registrar of Companies (ROC) the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. The Holding Company has achieved the required export obligation within the prescribed timeline.

b During the quarter ended 30 September 2025, the Holding Company reversed stamp duty payable to Government of National Capital Territory of Delhi on account of the merger of Medanta Holding Private Limited and the Holding Company, amounting to ₹ 159.85 millions, pursuant to adjudication of its stamp duty application.

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued draft Central Rules and related FAQs.

The Group has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group has presented the incremental charge relating to gratuity and compensated absences, aggregating to ₹365.98 millions under 'Exceptional items' in its consolidated unaudited financial results for the quarter and nine months ended 31 December 2025.

The Group continues to monitor the finalisation of the Central and State Rules and any further government clarifications on other aspects of the Labour Codes, and will record the accounting treatment as required based on future developments.

- 5 The Holding Company received in-principle approval for allotment of land measuring 3.5 acres from Assam Industrial Development Corporation Limited (a Government of Assam undertaking) during the quarter ended 30 September 2025. Further, during the quarter ended 31 December 2025, the Holding Company obtained physical possession of land.
- 6 During the period ended 31 December 2025, the Board of Directors of the Holding Company has approved the grant of 605,500 Options to certain eligible employees and allotted 183,000 shares to GHL Employees Welfare Trust under Part –A and Part- B respectively of GHL LTIP 2024 Plan.

**Employee benefits expense includes:**

Particulars	Quarter ended			Nine months ended		(₹ in millions)
	31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
Employee share based payment expense	103.15	100.04	-	281.96	-	-

- 7 Previous period figures have been regrouped/reclassified to conform to the current period's classification.



For and on behalf of the Board of Directors of Global Health Limited



  
Dr. Naresh Trehan  
Chairman and Managing Director

Place : Gurugram

Date : 04 February 2026






**Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**Annexure B**

S. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment	Mr. Malik Mohd. Ashhab appointed as one of the 'Senior Management Personnel' of the Company designated as 'Head-Diagnostic Services w.e.f. February 04, 2026.  He will lead the Retail Lab Business of the Group.
3.	Brief profile (in case of appointment)	Mr. Malik Mohd. Ashhab holds a Master's degree in Microbiology and has over 16 years of experience in the diagnostics sector, handling various roles and teams with renowned organizations like Dr. Lal PathLabs, Sterling Accuris Diagnostics, SRL/Agilus Diagnostics, and Redcliffe Labs.  Mr. Malik has skills with deep expertise, strong operational understanding with a sharp commercial and execution focus.
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA





**Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**Annexure C**

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Re-appointment of Dr. Ravi Gupta as a Non-Executive Independent Director of the Company for a second term of 5 (five) consecutive years with effect from July 08, 2026, subject to approval of the Shareholders.
3.	Brief profile (in case of appointment);	Dr. Ravi Gupta is a Non-Executive Independent Director of the Company. He was appointed on the Board on July 08, 2021. He did his graduation and post-graduation from Shri Ram College of Commerce. Thereafter, he did LL.B. from Delhi University and MBA (Finance) from Faculty of Management Studies, Delhi. He completed his Ph.D. from FMS. He was a faculty member at Shri Ram College of Commerce for over 36 years and also has vast practical experience in handling tax matters of trade and industry. He has addressed more than 2,000 seminars on Direct Taxes organised by ICAI, Chambers of Commerce, Universities, etc. He was appointed by the Government of India as a member of the Committee constituted for Simplification of Income Tax Act. He is also an independent director of many reputed companies including Varun Beverages Ltd., Dharampal Satyapal Ltd. etc. He had been nominated by the Government of India to the Central Council of the Institute of Chartered Accountants of India.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Dr. Ravi Gupta is not related to any Director of the Company.
5.	Information required pursuant to BSE and National Stock Exchange of India Ltd. circulars dated June 30, 2018	Dr. Ravi Gupta is not debarred from holding the office of director pursuant to any SEBI order or any other authority.




**Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**Annexure D**

S. No.	Particulars	Information of event
1.	Reason for change viz. <del>appointment</del> , re-appointment, <del>resignation</del> , <del>removal</del> , <del>death or otherwise</del> ;	Re-appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of <del>appointment</del> /re-appointment;	Re-appointment of Mr. Rajan Bharti Mittal as a Non-Executive Independent Director of the Company for a second term of 5 (five) consecutive years with effect from July 08, 2026, subject to approval of the Shareholders.
3.	Brief profile (in case of appointment);	<p>Mr. Rajan Bharti Mittal is a Non-Executive Independent Director of the Company. He was appointed on the Board on July 8, 2021. He holds a bachelor's degree in arts from Punjab University, Chandigarh, India and has completed 'Owner/ President Management Programme' from Harvard Business School, USA. He is one of India's leading conglomerates with diversified interests in Telecom, Space Communications, Digital Solutions, Financial Services, Real Estate, in addition to other ventures. Mr. Mittal serves as a member of several industry associations and policymaking bodies. He is currently an Honorary Member at the Board of Trustees of Brookings Institution, the world's oldest and most prestigious think tank and a member of the President's Council on International Activities (PCIA), Yale University.</p> <p>Mr. Mittal is amongst the Champions of EDISON Alliance at the World Economic Forum (WEF) - a cross-sector platform to accelerate collaborative action for digital inclusion. Mr. Mittal is a leading member of the WEF initiative on Alliance of CEO Climate Action Leaders India - a high-level platform for business leaders to support concrete plans and ideas to step up India's climate action and green transition efforts. He is also a member of the India-Singapore CEO Forum.</p>



		<p>He served as the President of the Federation of Indian Chambers of Commerce and Industry (FICCI) for the year 2009 - 2010 and is currently a Member of its Executive &amp; Steering Committees. He was also President of the International Chamber of Commerce (ICC) India in 2012-13. Mr. Mittal has been the President of Association of Basic Telecom Operators (now known as Association of Unified Telecom Service Providers of India - AUSPI) for 1999-2000.</p> <p>Mr. Mittal has been honoured with the "Indian Business Leader of the Year Award 2011" by Horasis, The Global Visions Community and has also been awarded the "Leonardo International Prize 2012" by Comitato Leonardo, the Italian Quality Committee."</p>
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Mr. Rajan Bharti Mittal is not related to any Director of the Company.
5.	Information required pursuant to BSE and National Stock Exchange of India Ltd. circulars dated June 30, 2018	Mr. Rajan Bharti Mittal is not debarred from holding the office of director pursuant to any SEBI order or any other authority.





**Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**Annexure E**

S. No.	Particulars	Information of event
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Appointment of Ms. Shonan Purie Trehan as a Non-Executive Non-Independent Director of the Company, liable to retire by rotation with effect from March 13, 2026, subject to approval of the Shareholders.
3.	Brief profile (in case of appointment);	<p>Ms. Shonan Purie Trehan has completed her Bachelor of Architecture at the Rhode Island School of Design (RISD), before gaining experience at Eisenman Architects in New York City and Le Groupe Arcop in Montreal, where she worked on large institutional and cultural projects. In 2008, she earned her Master's in Advanced Architectural Design from the Bartlett School of Built Environment, UCL, London.</p> <p>She has over 20 years of experience in the planning and design of primary, secondary and tertiary healthcare and other facilities, with direct involvement in projects totalling 5+ million sq ft and 4,000+ hospital beds across India and South Asia.</p> <p>She is the Founder and Principal Architect of Language Architecture Body (L.A.B.), a multidisciplinary architectural practice over forty architects and collaborators based in Mumbai and Florence. L.A.B. has completed over 80 projects across India including a few in the US &amp; Africa including education institutions, healthcare facilities, cultural centers, workplaces, hospitality, and residences.</p>



		<p>Ms. Trehan and L.A.B. have received national and international recognitions, including AD50, AD100, EDIDA and ID Honours, and have been finalists at the World Architecture Festival (Amsterdam, 2019 &amp; Lisbon, 2022). Alongside practice, she continues to engage in architectural education and discourse, contributing as a critic, lecturer, and mentor.</p> <p>As Founder and Principal Architect, Ms. Shonan Trehan leads the firm's Healthcare &amp; Institutional Division, overseeing medical planning, architectural design, and interior environments for large-scale hospitals, medical colleges, and research facilities. Her work integrates clinical efficiency, patient safety, infection control, and operational workflows, while embedding design strategies that support healing, dignity, and long-term adaptability.</p>
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Ms. Shonan Trehan is daughter of Dr. Naresh Trehan, the Promoter and Chairman & Managing Director of the Company. Her sister is spouse of Mr. Pankaj Sahni, Group CEO and Director of the Company.
5.	Information required pursuant to BSE and National Stock Exchange of India Ltd. circulars <i>dated</i> June 30, 2018	Ms Trehan is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

